- Home
- SNTI vs PETS Comparison
SNTI vs PETS Comparison
Compare SNTI & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNTI | PETS |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 63.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SNTI | PETS |
|---|---|---|
| Price | $1.23 | $2.91 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 1 |
| Target Price | ★ $9.00 | $3.20 |
| AVG Volume (30 Days) | 4.1M | ★ 6.9M |
| Earning Date | 11-13-2025 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $226,972,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $150.00 | $2.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $1.57 |
| 52 Week High | $5.96 | $6.08 |
Technical Indicators
Market Signals| Indicator | SNTI | PETS |
|---|---|---|
| Relative Strength Index (RSI) | 33.44 | 71.18 |
| Support Level | $1.34 | $1.69 |
| Resistance Level | $2.88 | $4.05 |
| Average True Range (ATR) | 0.24 | 0.25 |
| MACD | -0.10 | 0.17 |
| Stochastic Oscillator | 0.62 | 53.83 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.